Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (60)

II-01Brigitte Lacroix

Modeling the anti-drug antibody response in rheumatoid arthritis patients treated with certolizumab pegol

Wednesday 15:10-16:30

II-02

Population PK modeling and simulation to support dose selection of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenic patients.

Wednesday 15:10-16:30

II-03

Population modelling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs

Wednesday 15:10-16:30

II-04Cédric Laouenan

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients

Wednesday 15:10-16:30

II-05Anna Largajolli

The OFVPPC: A simulation objective function based diagnostic

Wednesday 15:10-16:30

II-06Jean Lavigne

Modeling and simulation of dihydroartemisinin (DHA) after administration of Eurartesim® (piperaquine tetraphosphate/DHA)

Wednesday 15:10-16:30

II-07Kha Le

Population PKPD Modeling of Geographic Atrophy Disease Progression, Target Mediated Disposition and Treatment Effect of Lampalizumab

Wednesday 15:10-16:30

II-08Jacob Leander

Estimation in stochastic differential mixed-effects models

Wednesday 15:10-16:30

II-09Robert Leary

Robust Importance Sampling for EM-based NLME Algorithms

Wednesday 15:10-16:30

II-10Joomi Lee

Population pharmacokinetic analysis of sumatriptan in healthy Korean male subjects

Wednesday 15:10-16:30

II-11Giulia Lestini

Two-stage adaptive designs in nonlinear mixed-effects models: an evaluation by simulation for a pharmacokinetic (PK) and pharmacodynamic (PD) model in oncology

Wednesday 15:10-16:30

II-12Yan Li

PK/PD Modeling of Tumor Growth Inhibition in Xenograft Mice to Optimize Experimental Design and Improve Study Efficiency

Wednesday 15:10-16:30

II-13

Evaluation of tetrahydrobiopterin responsiveness in neonates with hyperphenylalaninemia

Wednesday 15:10-16:30

II-14Andreas Lindauer

A tool for First-in-human PK Prediction Incorporating Experimental Uncertainty

Wednesday 15:10-16:30

II-15Jos Lommerse

PKPD model of erythropoietin and hemoglobin response in rats following administration of prolyl hydroxylase inhibitors

Wednesday 15:10-16:30

II-16

Developing a mechanistic physiologically based lung model and its application in modelling rifampicin pharmacokinetics in the lung

Wednesday 15:10-16:30

II-17

PPK analysis of Rouvastatin in Children and Adolescents (ages 6 to <18 years of age) with Familial Hypercholesterolemia to Support Regulatory Approval

Wednesday 15:10-16:30

II-18Mats Magnusson

A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy

Wednesday 15:10-16:30

II-19Victor Mangas-Sanjuan

Semi-mechanistic cell cycle PKPD model of chemotherapy-induced neutropenia

Wednesday 15:10-16:30

II-20Andreas Matthios

Dosing recommendation for gabapentin in chronic paediatric pain

Wednesday 15:10-16:30

II-21Johanna Melin

Population pharmacokinetic analysis of hydrocortisone in paediatric patients with adrenal insufficiency

Wednesday 15:10-16:30

II-22France Mentré

PFIM 4.0: new features for optimal design in nonlinear mixed effects models using R

Wednesday 15:10-16:30

II-23Matilde Merino-Sanjuán

Simulation of Plasmatic Taurine Levels In Well And Undernourished Rats After Enteral Diet Administration.

Wednesday 15:10-16:30

II-24Jay Mettetal

Preclinical cardiovascular risk assessment of PPAR-gamma agonist effects based on translational PK/PD modelling

Wednesday 15:10-16:30

II-25Enrica Mezzalana

A Target-Mediated Drug Disposition model to quantify the relationship between Otelixizumab in vitro concentration and TCR/CD3 engagement

Wednesday 15:10-16:30

II-26Raymond Miller

Modelling and simulation of the activity of intrinsic Factor Xa following edoxaban treatment

Wednesday 15:10-16:30

II-27Iris Minichmayr

Target site pharmacokinetics of doripenem in plasma and interstitial space fluid of peripheral tissues

Wednesday 15:10-16:30

II-28Dirk Jan Moes

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in liver transplant patients

Wednesday 15:10-16:30

II-29

Physiologically-based Pharmacokinetic (PBPK) modeling of the time-dependent drug-drug interaction (DDI) of clarithromycin and midazolam

Wednesday 15:10-16:30

II-30Hussain Mulla

Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration.

Wednesday 15:10-16:30

II-31Helen Musther

Are PBPK models reporting the right Cmax? Central venous versus peripheral site

Wednesday 15:10-16:30

II-32Flora Musuamba-Tshinanu

Optimisation of tacrolimus-based immunosuppressive treatment in pediatric solid organ transplantation: A model-based approach.

Wednesday 15:10-16:30

II-33Tafireyi Nemaura

In silico estimation of oral bioavailability: Implications to estimation of efavirenz PK parameters.

Wednesday 15:10-16:30

II-34Ida Neldemo

Predicting the absolute neutrophil count with frequent measurements during docetaxel-induced myelosuppression

Wednesday 15:10-16:30

II-35Yookhwan Noh

Population pharmacokinetics of HM781-36 and its metabolites in patients with advanced solid tumors

Wednesday 15:10-16:30

II-36Rikard Nordgren

Automatic binning for visual predictive checks

Wednesday 15:10-16:30

II-37Joakim Nyberg

Simulating large time-to-event trials in NONMEM

Wednesday 15:10-16:30

II-38Kayode Ogungbenro

A physiologically based pharmacokinetic model for 6-mercaptopurine in adults and children

Wednesday 15:10-16:30

II-39Sean Oosterholt

Covariate model selection in an Alzheimer disease progression model

Wednesday 15:10-16:30

II-40

Population pharmacokinetics of ALX-0171, an inhaled Respiratory Syncytial Virus (RSV) neutralizing Nanobody.

Wednesday 15:10-16:30

II-41Aziz Ouerdani

Tumor growth and angiogenesis inhibition modeling: Effects of pazopanib on preclinical and clinical tumor size data

Wednesday 15:10-16:30

II-42

Population K-PD modelling of lymph node size in lymphoma patients treated with abexinostat, a histone deacetylase inhibitor (HDACi).

Wednesday 15:10-16:30

II-43Eirini Panoilia

A population PK model for bevacizumab when combined with chemotherapy in patients with metastatic colorectal cancer stage IV

Wednesday 15:10-16:30

II-44Sung Min Park

Population pharmacokinetics and CYP3A5 genotype effect of S-amlodipine in healthy Korean male subjects

Wednesday 15:10-16:30

II-45Zinnia Parra-Guillen

Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer

Wednesday 15:10-16:30

II-46Sophie Peigné

Paediatric PK predictions and population analysis

Wednesday 15:10-16:30

II-47Nathalie Perdaems

Translational PKPD modeling of a cardiovascular drug and the interrelationship between blood pressure and heart rate in animals and human

Wednesday 15:10-16:30

II-48Jonás Samuel Pérez-Blanco

Population pharmacokinetic of doxorubicin and doxorubicinol in hematological patients

Wednesday 15:10-16:30

II-49Philippe Pierrillas

Preclinical evaluation of the dose-concentration-marker-tumor growth relationship of a new pro-apoptotic compound using population PK-PD modeling

Wednesday 15:10-16:30

II-50Elodie Plan

Item Response Theory Model as Support for Decision-Making: Simulation Example for Inclusion Criteria in Alzheimer’s Trial

Wednesday 15:10-16:30

II-51

A Prospective Population Pharmacokinetic (PK) Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria (PKU)

Wednesday 15:10-16:30

II-52Gauri Rao

Characterization of Oseltamivir Carboxylate (OC) Disposition using a Reduced Population (POP) Pharmacokinetic (PK) Model

Wednesday 15:10-16:30

II-53Yan Ren

Effect of Fluticasone Furoate Treatment on Cortisol Circadian Rhythm in Healthy Chinese Subjects

Wednesday 15:10-16:30

II-54Renhua Zheng

Population Compartmental approaches in bioequivalence studies

Wednesday 15:10-16:30

II-55Benjamin Ribba

On the use of model-based tumor size metrics to predict survival

Wednesday 15:10-16:30

II-56Clémence Rigaux

Modeling HbA1c dynamics in type II diabetes mellitus in patients treated with GLP-1 receptor agonist lixisenatide

Wednesday 15:10-16:30

II-57Rikke Meldgaard Røge

Modelling of Glucose and Insulin profiles in Patients with Type 2 Diabetes Mellitus treated with a GLP-1 analogue

Wednesday 15:10-16:30

II-58Hyerang Roh

Characterization of Nocturia Patient’s Urination Pattern and Assessment of Drug Treatment Using Joint Ordered Categorical Model

Wednesday 15:10-16:30

II-59Trine Høyer Rose

Dose-concentration-response modelling of inhibin B in controlled ovarian stimulation with FE 999049, a recombinant FSH derived from a human cell-line

Wednesday 15:10-16:30

II-60Adedeji Majekodunmi

Mixed Effect Modelling in HCV-HIV co-infected Children

Wednesday 15:10-16:30